Tag: USPTO
-
Patent Awarded for Engineered T-Cell Cancer Therapy
An experimental treatment using a person’s modified T-cells from the immune system to attack solid tumor cancers received a U.S. patent.
-
UC-Berkeley to Get New Crispr Patent
University of California in Berkeley will soon receive a new patent for its development of the genome editing process known as Crispr, the latest round in a years-long dispute.
-
Patent Set for Long-Term Drug Capsules
Techniques for delivering drugs in capsule form that last a week or longer in the patient are expected to receive a patent soon from U.S. authorities.
-
Company Formed to Advance Sickle Cell Gene Therapy
A Swiss medical technologies company and Cincinnati Children’s hospital in Ohio are starting a new enterprise to commercialize research on gene therapies for inherited blood disorders.
-
Patents Awarded for Stem Cell Heart Disease Technologies
A company developing treatments for heart disease using stem cells to regenerate healthy heart tissue received two new patents for techniques supporting its core processes.
-
Appeals Court Backs Broad Institute in Crispr Case
A U.S. appeals court supported the Broad Institute’s claims it invented a separate Crispr technology from University of California, affirming a previous U.S. patent office ruling.
-
Ultra-Sensitive Nanotech Robot Skin Receives Patent
Inventors of a system of sensors packaged in a thin film received a patent for their work that enables robotic devices to better sense conditions in the nearby environment.
-
UC-Berkeley Gains U.S. Crispr-Cas9 Patent
University of California received a patent for its genome editing technology known as Crispr, with the most widely used editing enzyme called Cas9.
-
Patent Awarded for Nanoparticle Drug, Cannabis Delivery
A delivery technology for therapeutic compounds in nanoscale natural oil particles received a U.S. patent, which the company owning the technology says can be applied to drugs, nutritional supplements, and cannabis-based treatments.
-
Patents Awarded for Genetic Editing of CAR T-Cells
U.S. patents were awarded to a biotechnology company developing therapies using the genomic editing process known as Crispr to create immune system cells with proteins for attacking cancer cells.